Cell News and Research

RSS

Banyan, Amarantus complete collaboration agreement related to TBI development program

Amarantus BioSciences, Inc., a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.

8 Jun 2012

dSarm/Sarm1 gene promotes axon destruction after injury

Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy.

8 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

IRCM researchers make important breakthrough in the field of immunology

A team of researchers at the IRCM led by Dr. Andr- Veillette made an important breakthrough in the field of immunology, which will be published online today by the scientific journal Immunity. The scientists explained a poorly understood molecular mechanism associated with a human immune disorder known as XLP disease or Duncan's syndrome.

8 Jun 2012

ReproCELL to begin commercialization of human iPS-derived neurons for Alzheimer's

ReproCELL, Inc. announces today that the company will start commercializing human iPS-derived neurons in which an Alzheimer's disease related gene has been incorporated.

8 Jun 2012

Study identifies molecular changes responsible for abnormal cholesterol production and metabolism

A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

Researchers identify brain receptor that appears to play a central role in regulating appetite

Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.

8 Jun 2012

Scientists discover new function for thrombospondin protein

Scientists have discovered a new function for a protein that protects cells during injury and could eventually translate into treatment for conditions ranging from cardiovascular disease to Alzheimer's.

8 Jun 2012

MGH, HSG to conduct PBT2 clinical trial in Huntington's disease

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.

8 Jun 2012

Adjuvant chemoradiotherapy boosts esophageal cancer survival

Chemoradiotherapy significantly improves the outcome of patients undergoing surgery for cancer of the esophagus or esophagogastric junction and is well tolerated, suggests research in The New England Journal of Medicine.

7 Jun 2012

Initial HSCT results from phase III trial on systemic sclerosis

Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

7 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer in the United States - in patients with basal cell nevus syndrome (BCNS), a rare genetic condition that causes hundreds to thousands of skin cancers primarily treated by surgical removal.

7 Jun 2012

Paper spotlights unique developmental strategy undertaken by all mammals

Ask the average person the street how the brain develops, and they'll likely tell you that the brain's wiring is built as newborns first begin to experience the world. With more experience, those connections are strengthened, and new branches are built as they learn and grow. A new study conducted in a Harvard lab, however, suggests that just the opposite is true.

7 Jun 2012

Targeting stem cells might be more effective in treating vascular disease

One of the top suspects behind killer vascular diseases is the victim of mistaken identity, according to researchers from the University of California, Berkeley, who used genetic tracing to help hunt down the real culprit.

7 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

Study describes how seizures in people with AS could be linked to brain cell activity imbalance

New research by scientists at the University of North Carolina School of Medicine may have pinpointed an underlying cause of the seizures that affect 90 percent of people with Angelman syndrome (AS), a neurodevelopmental disorder.

7 Jun 2012